Mineralys expands lorundrostat trial and with inhibitor combo for CKD treatment

Mineralys Therapeutics announced details of an expanded two-part Phase 2 clinical trial for lorundrostat as a potential therapy to treat patients with Stage 2 to 4 chronic kidney disease CKD , which is expected to start enrolling patients in the second half of 2023. “We are excited to move ahead with this trial to evaluate lorundrostat as a treatment for CKD….”This trial will allow us to evaluate the safety, efficacy and tolerability of lorundrostat alone and in combination with an SGLT2 inhibitor in CKD.” “Aldosterone contributes to the development and progression of chronic kidney disease through genomic and non-genomic signaling. The use of lorundrostat, an aldosterone synthase inhibitor or ASI, to inhibit aldosterone production may represent a more complete solution and promising approach to treat CKD patients,” stated David Rodman, M.D. FAHA, Chief Medical Officer of Mineralys Therapeutics. ..As this is an exploratory trial, interim data analyses may be conducted at one or more time points. Topline data from this trial is anticipated between Q4 2024 and Q1 2025.